Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Thrombotic events remains the most important safety issue for combined oral contraceptives. Despite a reduction in the dose of ethinyl estradiol and changesinthe type of progestogens, current formulations confer about 2 to 4-fold increased risk of venous thromboembolism.

Oral progestin-only contraception is often used in women at high risk for development of venous thromboembolism (history of venous thrombosis, hereditary thrombophilia,…). However, evidence for the safety of such a preparations is limited.

A meta-analysis of eight observational studies published in the British Medical Journal did not identify any association between oral progestin-only contraception and venous thromboembolism.

These data offer reassurance that current medical practices are appropriate.

 

© Esther 2019